February 15, 2018 / 7:29 AM / 7 months ago

BRIEF-Astrazeneca Says ‍Selumetinib In Nf1 Gets FDA Orphan Drug Status​

Feb 15 (Reuters) - Astrazeneca Plc:

* ‍SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS​

* US FDA GRANTED ORPHAN DRUG DESIGNATION (ODD) FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1)​

* ‍SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS​

* ‍PHASE II TRIAL RESULTS ARE EXPECTED LATER IN 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below